#USA #Tampa #neuroplastogens #Psilera #PSIL-006

Psilera Inc. Announces Participation in Key Industry Events

Psilera, Inc., a prominent biopharmaceutical company at the forefront of pioneering next-generation psychedelics and neuroplastogens, has confirmed its participation in two significant conferences aimed at investors and industry professionals next month. This strategic move marks an essential opportunity for Psilera to relay vital updates concerning its promising pipeline, particularly focusing on its lead candidate PSIL-006, which is progressing towards its first-in-human clinical trials.

Upcoming Conferences Overview

Psilera's management will engage directly with potential investors and partners at these events, which serve as platforms for sharing insights into the company's innovative approaches and the future of neuropharmacology.

Oppenheimer CNS and Neuro-Muscular Summit

• - Date: June 10, 2026
• - Location: Miami, FL
• - Speaker: Dr. Chris Witowski, Co-Founder and CEO
• - Discussion: Dr. Witowski will participate in an expert panel focused on the evolving field of CNS drug development. He will outline Psilera's unique approach to developing therapies that enhance neuroplasticity while reducing the risks associated with hallucinogenic effects and cardiovascular issues.

BIO International Convention

• - Date: June 22 – June 25, 2026
• - Location: San Diego, CA
• - Representatives: Dr. Chris Witowski and Dr. Magali Haas, Chief Medical Officer
• - Activities: The executive team will present the latest preclinical data to a selected audience of industry leaders and institutional investors. They aim to establish strategic partnerships and expand their collaborative network in anticipation of significant clinical milestones.

A Critical Time for Research

Dr. Chris Witowski expressed enthusiasm about the timing of these events, stating, "Following the recent federal policy prioritizing research in serious mental illnesses and neurological conditions, we are building momentum into a critical junction as we bridge the gap between our robust preclinical data and upcoming first-in-human studies. The demand for targeted, accessible neuroplastogens has never been higher."

This reflects Psilera's goal to revolutionize treatments for neurological disorders with their precision neuropharmacology platform. The upcoming conferences are expected to provide invaluable opportunities for dialogue with investors and key opinion leaders (KOLs) within the global biotech community.

For interested parties looking to connect with the Psilera Business Development team during these conferences, they can reach out via email at [email protected].

About Psilera, Inc.

Founded with a mission to advance the development of novel psychedelic therapies, Psilera, Inc. stands out in the biopharmaceutical landscape. Their pipeline encompasses pioneering therapeutic compounds, including the first-in-class neuroplastogen PSIL-006, which promises innovative solutions for treating a variety of neurological conditions. With a robust scientific team and an advanced drug-design platform, Psilera is dedicated to crafting scalable, effective, and patient-centered treatments.

For further details about their cutting-edge work, please visit www.psilera.com.

Press Contacts

Investors: Monique Kosse, Gilmartin Group - [email protected]
Media: Katie DeMarsh, Director of Marketing - [email protected]

This proactive engagement sets the stage not only for Psilera’s immediate goals but also for the broader evolution of treatments tailored to meet the complex needs of those facing mental health and neurological challenges.